Psychosocial distress in patients treated for cancer pain: A prospective observational study

Sean O’Mahony, MB BCh, BAO; Joseph Lucien Goulet, PhD; Richard Payne, MD

doi:10.5055/jom.2010.0019

Authors

Sean O’Mahony, MB BCh, BAO
Joseph Lucien Goulet, PhD
Richard Payne, MD

DOI:

https://doi.org/10.5055/jom.2010.0019

Keywords:

cancer pain, opioid medications, psychosocial wellbeing

Abstract

Introduction: Untreated emotional distress negatively impacts the management of cancer pain.
Objectives: The authors evaluated 64 patients with cancer pain who completed baseline and follow-up measures to identify if (1) measures of psychosocial wellbeing, pain intensity, and pain management were associated with survival time; (2) higher opioid doses were associated with less psychosocial distress; and (3) intrasubject correlations across time altered the relationship between pain, depression, social support, spirituality, and increased desire for hastened death (DHD).
Methods: The main outcome measures included the Brief Pain Inventory (BPI), Daily Morphine Equivalent Dose (DMED), Beck Depression Inventory-II (BDI-II), DHD scale, Bottomley Social Support Scale, FACIT Spiritual Well-Being Scale (FACIT-Sp), Karnofsky Performance Rating Scale (KPRS), and State-Trait Anxiety Inventory (STAI).
Results: There were significant differences between baseline and follow-up DHD (0.84 vs 1.38, p = 0.021) and BPI scores (6.36 vs 4.86, p < 0.001). Lower existential wellbeing was associated with reduced survival (HR = 0.78, p = 0.019); improvement in pain was associated with longer survival (HR = 1.33, p = 0.034). Higher religious wellbeing was associated with higher probability of survival to 1 year (HR = 0.41, p = 0.014), as was higher KPRS (HR = 0.97, p = 0.001) but not DMED > 300 mg. Higher existential distress and lower Bottomley scores were associated with higher hazard ratios for death at 1 year (HR = 2.78, p = 0.02) and (HR = 14.94, p = 0.002). There were significant differences in average BDI-II for persons with BPI > 7 versus those with moderate or mild pain (12.12 vs 6.82, p < 0.0001) and in DHD (1.71 vs 0.64, p = 0.002). Depression decreased in persons with DMED > 300 mg between baseline and follow-up (−1.67 vs 2.72, p = 0.024). Mean DHD was lower for persons whose pain improved versus others (0.96 vs 2.0, p = 0.026). A generalized linear model was conducted with DHD as the dependent variable and the other above variables as predictors. Higher existential wellbeing and KPRS were associated with lower DHD (β = −0.135, p = 0.049) and (β = −0.79, p = 0.006), respectively.
Conclusions: The major findings of this study are that in persons with cancer pain, lower social support and existential wellbeing, but not higher DMED, were associated with shorter survival time. Treatment of cancer pain was associated with lessening of emotional distress. Lower levels of existential wellbeing and physical performance status appear to be associated with greater DHD.

Author Biographies

Sean O’Mahony, MB BCh, BAO

Medical Director, Palliative Care Service, Montefiore Medical Center, Bronx, New York; Assistant Professor, Albert Einstein College of Medicine, Bronx, New York.

Joseph Lucien Goulet, PhD

Director, Methodology and Biostatistics Core, Pain Research, Informatics, Medical Comorbidities, and Education (PRIME) Center, Associate Research Scientist, Yale University School of Medicine, VA Connecticut Healthcare System, West Haven, Connecticut.

Richard Payne, MD

Professor of Medicine and Divinity, Esther Colliflower Director, Duke Institute on Care at the End of Life, Duke University Divinity School, Durham, North Carolina.

References

Woodforde JM, Fielding JR: Pain and cancer. J Psychosom Res. 1970; 14: 365-370.

Ahles TA, Blanchard EB, Ruckdeschel JC: Multidimensional nature of cancer-related pain. Pain. 1983; 17: 277-288.

Chochinov HM, Kristjanson LJ, Hack TF, et al.: Personality, neuroticism and coping towards the end of life. J Pain Symptom Manage. 2006; 32(4): 332-341.

Dalton JA, Feuerstein M: Fear, alexithymia and cancer pain. Pain. 1989; 38(2): 159-170.

Syrjala KL, Chapko MK, Vitaliano PP, et al.: Evidence for a biopsychosocial model of cancer treatment-related pain. Pain. 1995; 61(1): 69-79.

Zaza C, Baine N: Cancer pain and psychosocial factors: A critical review of the literature. J Pain Symptom Manage. 2002; 24(5): 526-542.

Derogatis LR, Morrow GR, Fetting J, et al.: The prevalence of psychiatric disorders among cancer patients. JAMA. 1983; 249(6): 751-757.

Spiegel D, Sands S, Koopman C: Pain and depression in patients with cancer. Cancer. 1994; 74(9): 2570-2578.

Turk D, Sist T, Okifuji A, et al.: Adaptation to cancer pain, regional/local cancer pain and non-cancer pain: Role of psychological and behavioural factors. Pain. 1998; 74(2): 247-256.

Passik SD, Dugan W, Mcdonald MV, et al.: Oncologists’ recognition of depression in their patients with cancer. J Clin Oncol. 1998; 16(4): 1594-1600.

Hewitt M, Rowland JH: Mental health service use among adult cancer survivors: Analysis of the national health interview survey. J Clin Oncol. 2002; 20 (23): 4581-4590.

Van Servellen G, Sarna L, Padilla G, et al.: Emotional distress in men with life-threatening illnesses. Int J Nurs Stud. 1996; 33(5): 551-565.

Bodurka-Bevers D, Basen-Engquist K, Carmack CL, et al.: Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol. 2000; 78(3): 302-308.

O’Mahony S, Kornblith A, Goulet JL, et al.: Desire for hastened death, cancer pain and depression: Report of a longitudinal observational study. J Pain Symptom Manage. 2005; 29(5): 446-457.

Folstein MF, Folstein SE, McHugh PR: Mini-mental state. J Psychiatr Res. 1975; 12(3): 189-195.

Chochinov HM, Wilson KG, Enns M, et al.: Desire for death in the terminally ill. Am J Psychiatry. 1995; 152: 1185-1191.

Cleeland CS, Ryan KM: Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994; 23(2): 129-138.

Endicott J: Measurement of depression in patients with cancer. Cancer. 1984; 53(10 Suppl): 2243-2248.

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: IV. Washington DC: American Psychiatric Association, 1994.

Spielberger CD: Manual for the State-Trait Anxiety Inventory (STAI). Palo Alto, CA: Consulting Psychologists Press, 1983.

Bottomley A, Jones L: The development of the Bottomley Cancer Social support scale. Eur J Cancer Care. 1995; 4(3): 127-132.

Peterman AH, Fitchett G, Brady MJ, et al.: Measuring spiritual-well being in people with cancer: The Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale (FACIT-Sp). Ann Behav Med. 2002; 24(1): 49-56.

Brady MJ, Peterman AH, Fitchett G, et al.: A case for including spirituality in quality of life measurement in oncology. Psychooncology. 1999; 8(5): 417-428.

Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer. In McLeod CM (ed.): Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press, 1949: 191-205.

Buccheri G, Ferrigno D, Tamburini M: Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 1996; 32(7): 1135-1141.

Pereira J, Lawlor P, Vigano A, et al.: Equianalgesic dosing ratios for opioids: A critical review and proposals for long-term dosing. J Pain Symptom Manage. 2001; 22(2): 672-687.

Portenoy R, Sibirceva R, Smout S, et al.: Opioid use and survival at the end of life: A survey of a hospice population. J Pain Symptom Manage. 2006; 32(6): 532-540.

Good PD, Ravenscroft PJ, Cavenagh J: Effects of opioids and sedatives on survival in an Australian inpatient palliative care population. Int Med J. 2005; 35(9): 512-519.

Morita T, Tsunoda J, Inoue S, et al.: Effects of high dose opioids and sedatives on survival in terminally ill cancer patients. J Pain Symptom Manage. 2001; 21(4): 282-289.

Thorns A, Sykes N: Opioid use in the last week of life and implications for end-of-life decision-making. Lancet. 2000; 356: 398-399.

van der Lee ML, van der Bom JG, Swarte NB: Euthanasia and depression: A prospective cohort study among terminally ill cancer patients. J Clin Oncol. 2005; 23(27): 6607-6612.

Emanuel EJ: Depression, euthanasia and improving end-of-life care. J Clin Oncol. 2005; 23(27): 6456-6458.

Ganzini L, Goy ER, Dobscha SK: Oregonian’s reasons for requesting physician aid in dying. Arch Intern Med. 2009; 169(5): 489-492.

Walker J, Waters RA, Murray G: Better off dead: Suicidal thoughts in cancer patients. J Clin Oncol. 2008; 26(29): 4725-4730.

Miller M, Mogun H, Arazel D: Cancer and the risk of suicide in older Americans. J Clin Oncol. 2008; 26(9): 4720-4724.

Bakitas, M, Lyons K, Hegel TM, et al.: Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: The Project ENABLE II Randomized Controlled Trial. JAMA. 2009; 302(7): 741-749.

Northouse L, Templin T, Mood D: Couples adjustment to breast disease during the first year following diagnosis. J Behav Med. 2001; 24(2): 115-136.

Koopman C, Angell K, Turner-Cobb JM, et al.: Distress, coping and social support among rural women recently diagnosed with primary breast cancer. Breast J. 2001; 7(1): 25-33.

Breitbart W, Rosenfeld B, Pessin H, et al.: Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA. 2000; 284(22): 2097-2911.

Fox BH: The role of psychological factors in cancer incidence and prognosis. Oncology. 1995; 9(3): 245-253.

Schroepfer TA: Social relationships and their role in the consideration to hasten death. Gerontologist. 2008; 48: 612-621.

Tait GR, Hodges BD: End-of-life care education for psychiatric residents: Attitudes, preparedness, and conceptualizations of dignity. Acad Psychiatry. 2009; 33: 451-456.

Ellis J, Lin J, Walsh A, et al.: Predictors of referral for specialized oncology care in patients with metastatic cancer: The contributions of age, distress, and marital status. J Clin Oncol. 2009; 27(5): 699-705.

Chochinov HM: Dying, dignity, and new horizons in palliative end-of-life care. Cancer J Clin. 2006; 56: 84-103.